Skip to main content
Erschienen in: Drug Safety 5/2008

01.05.2008 | Original Research Article

Inhaled Corticosteroids and the Risk of Fractures in Older Adults

A Systematic Review and Meta-Analysis

verfasst von: Dr Mahyar Etminan, Mohsen Sadatsafavi, Saeedreza Ganjizadeh Zavareh, Bahi Takkouche, J. Mark FitzGerald

Erschienen in: Drug Safety | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Background: Inhaled corticosteroids (ICS) are commonly prescribed medications for the management of asthma and chronic obstructive pulmonary disease. It is well established that long-term use of these drugs may lower bone mineral density. However, whether ICS increase the risk of fractures remains unknown. Recent studies that have attempted to explore this risk have had conflicting results. We sought to explore the risk of ICS and fractures among older adults by conducting a systematic review and meta-analysis of the literature.
Methods: We systematically searched several databases, including MEDLINE, EMBASE and the Cochrane Library, to identify pertinent studies.Those studies that potentially met our inclusion criteria were identified by two reviewers. Relative risks (RRs) were pooled using the random effects model. We also explored dose-response by stratifying the analysis on high and low doses of ICS. Heterogeneity was assessed using the Q statistic and publication bias was assessed using the funnel plot.
Results: Thirteen studies, including four randomized controlled trials, were included in the review. The pooled RRs for hip fractures and any fractures were 0.91 (95% CI 0.87, 0.96) and 1.02 (95% CI 0.96, 1.08), respectively. When we restricted the analysis to users of high-dose ICS, the pooled RRs for any fractures and hip fractures were 1.30 (95% CI 1.07, 1.58) and 1.32 (95% CI 0.90, 1.92), respectively. The funnel plot did not show evidence of publication bias.
Conclusion: We found no association between the use of ICS and fractures in older adults. A slight increase in risk was seen in those using high-dose ICS. The significance of this association should be investigated further.
Literatur
1.
Zurück zum Zitat Viegi G, Scognamiglio S, Baldacci F, et al. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 2001; 68: 4–19PubMedCrossRef Viegi G, Scognamiglio S, Baldacci F, et al. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 2001; 68: 4–19PubMedCrossRef
2.
Zurück zum Zitat Buckley NS, Salopeter SR. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol 2006; 31: 210–30 Buckley NS, Salopeter SR. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol 2006; 31: 210–30
3.
Zurück zum Zitat Motimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol 2005; 94: 15–21CrossRef Motimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol 2005; 94: 15–21CrossRef
4.
Zurück zum Zitat Johnell O, Pauwels R, Lofdahl CG, et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 2002; 19: 1058–63PubMedCrossRef Johnell O, Pauwels R, Lofdahl CG, et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 2002; 19: 1058–63PubMedCrossRef
5.
Zurück zum Zitat Hubbard RB, Smith CJ, Smeeth L, et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002; 166: 1563–6PubMedCrossRef Hubbard RB, Smith CJ, Smeeth L, et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002; 166: 1563–6PubMedCrossRef
6.
Zurück zum Zitat Lee TA, Weiss KB. Fracture risk associated with inhaled corti-costeroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 855–9PubMedCrossRef Lee TA, Weiss KB. Fracture risk associated with inhaled corti-costeroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 855–9PubMedCrossRef
7.
Zurück zum Zitat Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89PubMedCrossRef Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89PubMedCrossRef
8.
Zurück zum Zitat Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000 19; 283(15): 2008–12PubMedCrossRef Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000 19; 283(15): 2008–12PubMedCrossRef
9.
Zurück zum Zitat Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354(9193): 1896–900PubMedCrossRef Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354(9193): 1896–900PubMedCrossRef
10.
Zurück zum Zitat Scanlon PD, Connett JE, Wise RA, et al. Lung Health Study Research Group. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 2004; 170: 1302–9PubMedCrossRef Scanlon PD, Connett JE, Wise RA, et al. Lung Health Study Research Group. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 2004; 170: 1302–9PubMedCrossRef
11.
Zurück zum Zitat Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948–53PubMedCrossRef Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948–53PubMedCrossRef
12.
Zurück zum Zitat Suissa S, Baltzan M, Kremer R, et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004; 169: 83–8PubMedCrossRef Suissa S, Baltzan M, Kremer R, et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004; 169: 83–8PubMedCrossRef
13.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med 2005; 257: 374–84PubMedCrossRef Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med 2005; 257: 374–84PubMedCrossRef
14.
Zurück zum Zitat Johannes CB, Schneider GA, Dube TJ, et al. The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. Chest 2005; 127: 89–97PubMedCrossRef Johannes CB, Schneider GA, Dube TJ, et al. The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. Chest 2005; 127: 89–97PubMedCrossRef
15.
Zurück zum Zitat de Vries F, Pouwels S, Lammers JW, et al. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 2007; 261: 170–7PubMed de Vries F, Pouwels S, Lammers JW, et al. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 2007; 261: 170–7PubMed
16.
Zurück zum Zitat de Vries F, van Staa TP, Bracke MS, et al. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 2005; 25: 879–84PubMedCrossRef de Vries F, van Staa TP, Bracke MS, et al. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 2005; 25: 879–84PubMedCrossRef
17.
Zurück zum Zitat Baltzan MA, Suissa S, Bauer DC, et al. Hip fractures attributable to corticosteroid use. Study of Osteoporotic Fractures Group. Lancet 1999; 353: 1327PubMedCrossRef Baltzan MA, Suissa S, Bauer DC, et al. Hip fractures attributable to corticosteroid use. Study of Osteoporotic Fractures Group. Lancet 1999; 353: 1327PubMedCrossRef
18.
Zurück zum Zitat Lau E, Mamdani M, Tu K. Inhaled or systemic corticosteroids and the risk of hospitalization for hip fracture among elderly women. Am J Med 2003; 114: 142–5PubMedCrossRef Lau E, Mamdani M, Tu K. Inhaled or systemic corticosteroids and the risk of hospitalization for hip fracture among elderly women. Am J Med 2003; 114: 142–5PubMedCrossRef
19.
Zurück zum Zitat Hubbard R, Tattersfield A, Smith C, et al. Use of inhaled corticosteroids and the risk of fracture. Chest 2006; 130: 1082–8PubMedCrossRef Hubbard R, Tattersfield A, Smith C, et al. Use of inhaled corticosteroids and the risk of fracture. Chest 2006; 130: 1082–8PubMedCrossRef
20.
Zurück zum Zitat Costa-Bouzas J, Takkouche B, Cadarso-Suarez C, et al. HEpiMA: software for the identification of heterogeneity in meta-analysis. Comput Methods Programs Biomed 2001; 64: 101–7PubMedCrossRef Costa-Bouzas J, Takkouche B, Cadarso-Suarez C, et al. HEpiMA: software for the identification of heterogeneity in meta-analysis. Comput Methods Programs Biomed 2001; 64: 101–7PubMedCrossRef
21.
Zurück zum Zitat van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16: 581–8PubMedCrossRef van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16: 581–8PubMedCrossRef
22.
Zurück zum Zitat Fletcher AE, Jones DJ, Bulpitt CJ, et al. The MRC trial of assessment and management of older people in the community: objectives, design and interventions. BMC Health Services Res 2002; 2(1): 1–10CrossRef Fletcher AE, Jones DJ, Bulpitt CJ, et al. The MRC trial of assessment and management of older people in the community: objectives, design and interventions. BMC Health Services Res 2002; 2(1): 1–10CrossRef
23.
Zurück zum Zitat Tomlinson JE, McMashon AD, Chaudhuri R, et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005; 60: 282–7PubMedCrossRef Tomlinson JE, McMashon AD, Chaudhuri R, et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005; 60: 282–7PubMedCrossRef
24.
Zurück zum Zitat Van Staa TP, Leufkens B, Cooper C. Bone loss and inhaled gluccorticoids [letter]. New Engl J Med 2002; 346: 533PubMedCrossRef Van Staa TP, Leufkens B, Cooper C. Bone loss and inhaled gluccorticoids [letter]. New Engl J Med 2002; 346: 533PubMedCrossRef
Metadaten
Titel
Inhaled Corticosteroids and the Risk of Fractures in Older Adults
A Systematic Review and Meta-Analysis
verfasst von
Dr Mahyar Etminan
Mohsen Sadatsafavi
Saeedreza Ganjizadeh Zavareh
Bahi Takkouche
J. Mark FitzGerald
Publikationsdatum
01.05.2008
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 5/2008
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200831050-00005

Weitere Artikel der Ausgabe 5/2008

Drug Safety 5/2008 Zur Ausgabe

Conference Paper

Cosmetovigilance